A drug used to treat lead poisoning is now in short supply after Akorn Pharmaceuticals filed for bankruptcy and many of its products were recalled this spring.
Akorn's Generic Ciprofloxacin, Dexamethasone Receives Approval in the U.S.
Enforcement Report - Week of June 7, 2023
GURNEE, Ill., May 3, 2023 /PRNewswire/ -- Akorn Operating Company LLC has filed Chapter 7 bankruptcy on February 23, 2023. In connection with that filing, the company has ceased and shutdown all operations and terminated all its employees of all domestic US Sites. The Akorn Trustee is initiating a voluntary recall of various within-expiry human and animal products as a result of the closures and discontinuation of the Quality activities of these marketed products. (Refer to Attachment I and II*). The discontinuation of the Quality program means the company will not be able to support or guarantee that the products will meet all intended specifications through the labeled shelf life of the product. Further distribution or use of any remaining product on the market should cease immediately.
The beginning of March saw manufacturer Akorn Pharmaceuticals file for Chapter 7 bankruptcy protection, which led to the closure of all its US manufacturing plants and hundreds of layoffs. But this also had a cascading effect leading to a shortage of albuterol, specifically the 0.5% version, which is used to treat breathing issues.
Akorn, the “sole manufacturer” of a certain dose of liquid albuterol, has stopped production, FDA tweeted Wednesday. Two weeks ago, Akorn filed for bankruptcy and mothballed its U.S. operations. The closure swept up facilities like Akorn’s Decatur, Illinois, manufacturing plant, which was licensed to make the specific form of the drug in shortage.
The generic drug manufacturer Akorn Pharmaceuticals has filed for bankruptcy and will close its facilities across the US, liquidate its assets and end operations, it said in a court filing.
After years of navigating regulatory woes and financial troubles, Akorn Pharmaceuticals is calling it quits.
Generics player Akorn Pharmaceuticals said today that it’s shuttering a sterile manufacturing site in Decatur, IL and laying off up to 400 employees, according to LinkedIn posts and a WARN notice.